SABCS 2024

More testing - more surgery?

To Omit or Not to Omit: Rethinking SNL Biopsy

Challenging the first line treatment and chemotherapy - what is our first line treatment of choice in the future?

Practice changing combinations, treatment beyond progression and the art of medicine

CDK4/6i and ADC therapy for HER2+ and many more ADC options to come!

FASCINATE-N – GS1-04

PATINA – GS2-12

Ambivalent feelings about immunotherapy, but reassuring data for BRCA testing!

GeparDouze – GS3-05

CamRelief – GS3-06

OlympiA GS1-09

New data on CDK4/6i, oral SERDs and combinations, and evaluations

RW OS CDK4/6i – PS2-03

EMBER-3 – GS1-01

ADAPT – GS3-04

Older EBC patients should also undergo surgery

Who need anthracyclines for node-negative HR+ BC

Olaparib after (neo)adjuvant chemotherapy

No axillary surgery necessary in selected patients

The beginning of the end of sentinel lymph nodes

BRCA-mut population - impact of surgery & OlympiA - update analysis

ctDNA in follow-up - not for everyday clinical practice, but for clinical trials

From the ZEST study to the german SURVIVE study

Exciting updates on OlympiA

My highlights of SABCS 2024

Time to limit postmastectomy radiotherapy indications

Survival benefit for patients with risk-reducing surgery

Risk reducing mastectomy in patients with BRCA mutation

Fine-tuning of chemotherapy in node-negative luminal HR+/HER2- patients

Who needs chemotherapy?

Targets are important in EBC

Phase 2 neoadjuvant study with HER3 DXd

Is Margetuximab better than trastuzumab?

Fascinating data from Shanghai

Equivalence to chemotherapy with the combination of anti-HER2+, ET and palbociclib

Neo-adjuvant monitoring with MRT & US can reduce therapy duration

KEYNOTE-522 Interim analysis 4: Biomarkers

Atezolizumab does not improve EFS in TNBC

Biomarker analysis from the A-Brave trial

Czas na ograniczenie wskazań do radioterapii po mastektomii

Étude de phase 2 néoadjuvante avec HER3 DXd

Jaka chemioterapia u chorych na raki ER+/HER2- bez zajęcia węzłów chłonnych?

Analisi dei biomarcatori nello studio A-Brave

Equivalencia a la quimioterapia con la combinación de anti-HER2+, ET y palbociclib

I bersagli sono importanti nella EBC

Studio neoadiuvante di fase 2 con HER3 DXd

I miei punti di forza di SABCS 2024

OlympiA

Population BRCA-mut - impact de la chirurgie & OlympiA - analyse actualisée

Abstract Nr. 1: Imlunestrant

New SERD in phase-3-trial & CDK4/6 inhibitor in HR+ MBC

EMBER-3

CDK4/6 inhibitor + ET is the best start for HR+ Patients

Comparison of all CDK4/6 in combination with AI in the US Real-Word Setting

Targeting endocrine pathways is superior to Chemo in high-risk MBC patients

Efficacy data of EMBER-3

CDK4/6i more equal than not

DESTINY-Breast 12: Quality of life

HER2DX might optimize 1st line in HER2+ mBC

Optimizing 1st line treatment with T-DXd followed HP in HER2+ mBC

CDK4/6 inhibitor in HER2+ metastatic BC

Practice changing results for ER+/HER2+ patients

Significant and clinical relevant benefit of the addition of palbociclib as maintenance therapy in ER+ / HER2+ ABC

CDK4/6 inhibitors effective also in luminal HER2+ cancers

Nouveau SERD en phase 3 d'essai & Inhibiteur CDK4/6 dans le MBC HR+

Optimización del tratamiento de 1ª línea con T-DXd seguido de HP en CMM HER2+.

Beneficio significativo y clínicamente relevante de la adición de palbociclib como terapia de mantenimiento en ER+ / HER2+ ABC

HER2DX podría optimizar la 1ª línea en el CMM HER2+.

Il targeting delle vie endocrine è superiore alla CT nelle pazienti MBC ad alto rischio

Dati di efficacia di EMBER-3

Inhibitory CDK4/6 skuteczne również w rakach luminalnych HER2+